U.S. Physical Therapy Inc. (NYSE:USPH) CEO Christopher J. Reading sold 8,000 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $64.01, for a total value of $512,080.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

U.S. Physical Therapy Inc. (NYSE:USPH) opened at 63.00 on Thursday. U.S. Physical Therapy Inc. has a 52 week low of $42.59 and a 52 week high of $64.89. The company has a 50-day moving average of $62.44 and a 200-day moving average of $56.92. The stock has a market capitalization of $788.76 million, a price-to-earnings ratio of 32.47 and a beta of 0.76.

U.S. Physical Therapy (NYSE:USPH) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. U.S. Physical Therapy had a net margin of 6.95% and a return on equity of 12.06%. The firm earned $90.40 million during the quarter, compared to analysts’ expectations of $90.01 million. During the same period in the previous year, the company earned $0.51 earnings per share. U.S. Physical Therapy’s quarterly revenue was up 8.5% compared to the same quarter last year. Analysts anticipate that U.S. Physical Therapy Inc. will post $1.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 2nd. Stockholders of record on Friday, August 19th were issued a $0.17 dividend. The ex-dividend date of this dividend was Wednesday, August 17th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.08%. U.S. Physical Therapy’s payout ratio is 34.87%.

Several large investors have recently made changes to their positions in the stock. Mason Street Advisors LLC acquired a new stake in shares of U.S. Physical Therapy during the second quarter worth approximately $147,000. Schwab Charles Investment Management Inc. boosted its stake in shares of U.S. Physical Therapy by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 46,022 shares of the company’s stock worth $2,771,000 after buying an additional 810 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new stake in shares of U.S. Physical Therapy during the second quarter worth approximately $440,000. Fiera Capital Corp acquired a new stake in shares of U.S. Physical Therapy during the second quarter worth approximately $801,000. Finally, Arizona State Retirement System boosted its stake in shares of U.S. Physical Therapy by 1.6% in the second quarter. Arizona State Retirement System now owns 6,500 shares of the company’s stock worth $391,000 after buying an additional 100 shares during the last quarter. 98.33% of the stock is owned by institutional investors and hedge funds.

USPH has been the topic of a number of research reports. Zacks Investment Research raised shares of U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a research note on Tuesday, August 9th. Jefferies Group set a $65.00 price target on shares of U.S. Physical Therapy and gave the company a “hold” rating in a research note on Friday, August 5th. Finally, Barrington Research lowered shares of U.S. Physical Therapy from an “outperform” rating to a “market perform” rating in a research note on Friday, August 5th.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

5 Day Chart for NYSE:USPH

Receive News & Ratings for U.S. Physical Therapy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.